Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 17 (3), 349-356

Adherence to Asacol Once Daily Versus Divided Regimen for Maintenance Therapy in Ulcerative Colitis: A Prospective, Multicenter, Randomized Study

Affiliations

Adherence to Asacol Once Daily Versus Divided Regimen for Maintenance Therapy in Ulcerative Colitis: A Prospective, Multicenter, Randomized Study

Soo-Kyung Park et al. Intest Res.

Abstract

Background/aims: A once-daily (OD) regimen of 5-aminosalicylic acid (5-ASA) was easier to comply with than a divided daily (DD) regimen, and that treatment efficacy for ulcerative colitis (UC) was not affected by the dosing regimen. This study evaluated treatment adherence of OD and DD dosing in the Korean UC patients.

Methods: This study was a prospective, multicenter, randomized trial. UC patients were enrolled who have been in remission for more than 3 months. Patients were randomly assigned to the OD or DD group in a 1:1 ratio. The primary endpoint was adherence rate measured by tablet counts and self-reported adherence rate at 3, 6, 9, and 12 months. The relapse rate was measured at 1 year.

Results: Data from the 180 patients who were randomized were analyzed. Both self-reported adherence rate and adherence rate measured by tablet counts were not different at every points, including 1 year. The patients' satisfaction of the OD group was higher than that of the DD group (P<0.001). At 1 year, 91.2% and 95.5% of patients in the OD group and DD group had maintained clinical remission, respectively (P=0.37).

Conclusions: The adherence rates were not different between the OD group and DD group. The patients' satisfaction was higher in the OD group than in the DD group. 5-ASA OD dosing might have the same effect as DD for the maintenance of UC remission.

Keywords: Colitis, ulcerative; Inflammatory bowel disease; Mesalamine.

Conflict of interest statement

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1.
Fig. 1.
Patient enrollment and follow-up during the trial. OD, once daily; DD, divided daily.
Fig. 2.
Fig. 2.
Proportion of patients whose adherence was lower than 90%. (A) Self-reported adherence. (B) Adherence measured by tablet counts in the once daily (OD) group versus the divided daily (DD) group.

Similar articles

See all similar articles

References

    1. Choi CH, Kim YH, Kim YS, et al. Guidelines for the management of ulcerative colitis. Korean J Gastroenterol. 2012;59:118–140. - PubMed
    1. Choi CH, Moon W, Kim YS, et al. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7–37. - PMC - PubMed
    1. Wei SC, Chang TA, Chao TH, et al. Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. Intest Res. 2017;15:266–284. - PMC - PubMed
    1. Hanauer SB, Sninsky CA, Robinson M, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. Ann Intern Med. 1996;124:204–211. - PubMed
    1. Kao J, Kwok K, Das KM. Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended-release mesalamine. J Clin Gastroenterol. 2010;44:531–535. - PubMed
Feedback